

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-19. (Canceled)

20. (Previously presented) A purified peptide consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or a
pharmacologically acceptable salt thereof.

21-79. (Canceled)

80. (Currently amended) A purified peptide consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) (~~SEQ ID NO:31~~).

81. (Previously presented) A pharmacologically acceptable salt of a purified peptide
consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31).

82. (Previously presented) A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or a
pharmacologically acceptable salt thereof, wherein the peptide activates the guanylate cyclase C
receptor.

83. (Previously presented) A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31), wherein
the peptide activates the guanylate cyclase C receptor.

84. (Previously presented) A pharmacologically acceptable salt of a purified peptide
comprising the amino acid sequence:

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) , wherein
the peptide activates the guanylate cyclase C receptor.

85. (Previously presented) A pharmaceutical composition comprising the purified
peptide of any of claims 20 and 80-84 and a pharmaceutically acceptable carrier or excipient.

86. (Previously presented) A pharmaceutical composition comprising:

(a) a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or a pharmacologically acceptable salt
thereof; and

(b) a pharmaceutically acceptable carrier or excipient.

87. (Previously presented) A pharmaceutical composition comprising:

(a) a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and

(b) a pharmaceutically acceptable carrier or excipient.

88. (Previously presented) A pharmaceutical composition comprising:

(a) a pharmacologically acceptable salt of a purified peptide consisting of the amino
acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31);
and

(b) a pharmaceutically acceptable carrier or excipient.

89. (Previously presented) A pharmaceutical composition comprising:
- (a) a purified peptide comprising the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or a pharmacologically acceptable salt thereof; and
- (b) a pharmaceutically acceptable carrier or excipient.
90. (Previously presented) A pharmaceutical composition comprising:
- (a) a purified peptide comprising the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and
- (b) a pharmaceutically acceptable carrier or excipient.
91. (Previously presented) A pharmaceutical composition comprising:
- (a) a pharmacologically acceptable salt of a purified peptide comprising the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and
- (b) a pharmaceutically acceptable carrier or excipient.
92. (Previously presented) A method for increasing intestinal motility in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.
93. (Previously presented) A method for treating a patient suffering from irritable bowel syndrome, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.
94. (Previously presented) The method of claim 93 wherein the patient is suffering from constipation-predominant irritable bowel syndrome.

95. (Currently amended) The method of claim 93 wherein the patient is suffering from alternating[[-predominant]] irritable bowel syndrome.

96. (Previously presented) A method for treating constipation in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

97. (Previously presented) The method of claim 96 wherein the patient is suffering from chronic constipation.

98. (Previously presented) The method of claim 96 wherein the patient is suffering from idiopathic constipation.

99. (Previously presented) The method of claim 96 wherein the patient is suffering from post-operative ileus.

100. (Previously presented) The method of claim 96 wherein the constipation is caused by opiate use.

101. (Canceled)

102. (Previously presented) A method for treating dyspepsia in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

103. (Previously presented) A method for treating gastroparesis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

104. (Previously presented) A method for treating chronic intestinal pseudo obstruction in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

105. (Previously presented) A method for treating Crohn's disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

106. (Previously presented) A method for treating ulcerative colitis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

107. (Previously presented) A method for treating inflammatory bowel disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85.

108.-111. (Canceled)

112. (New) A method for increasing intestinal motility in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

113. (New) A method for increasing intestinal motility in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

114. (New) A method for increasing intestinal motility in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

115. (New) A method for increasing intestinal motility in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.

116. (New) A method for treating a patient suffering from irritable bowel syndrome, the method comprising administering to the patient an effective of amount of the pharmaceutical composition of claim 87.

117. (New) A method for treating a patient suffering from irritable bowel syndrome, the method comprising administering to the patient an effective of amount of the pharmaceutical composition of claim 88.

118. (New) A method for treating a patient suffering from irritable bowel syndrome, the method comprising administering to the patient an effective of amount of the pharmaceutical composition of claim 90.

119. (New) A method for treating a patient suffering from irritable bowel syndrome, the method comprising administering to the patient an effective of amount of the pharmaceutical composition of claim 91.

120. (New) The method of any of claims 116-119 wherein the patient is suffering from constipation-predominant irritable bowel syndrome.

121. (New) The method of any of claims 116-119 wherein the patient is suffering from alternating irritable bowel syndrome.

122. (New) A method for treating constipation in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

123. (New) A method for treating constipation in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

124. (New) A method for treating constipation in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

125. (New) A method for treating constipation in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.

126. (New) The method of any of claims 122-125 wherein the patient is suffering from chronic constipation.

127. (New) The method of any of claims 122-125 wherein the patient is suffering from idiopathic constipation.

128. (New) The method of any of claims 122-125 wherein the patient is suffering from post-operative ileus.

129. (New) The method of any of claims 122-125 wherein the constipation is caused by opiate use.

130. (New) A method for treating dyspepsia in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

131. (New) A method for treating dyspepsia in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

132. (New) A method for treating dyspepsia in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 89.

133. (New) A method for treating dyspepsia in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

134. (New) A method for treating gastroparesis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

135. (New) A method for treating gastroparesis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

136. (New) A method for treating gastroparesis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

137. (New) A method for treating gastroparesis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.

138. (New) A method for treating chronic intestinal pseudo obstruction in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

139. (New) A method for treating chronic intestinal pseudo obstruction in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

140. (New) A method for treating chronic intestinal pseudo obstruction in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

141. (New) A method for treating chronic intestinal pseudo obstruction in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.

142. (New) A method for treating Crohn's disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

143. (New) A method for treating Crohn's disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

144. (New) A method for treating Crohn's disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

145. (New) A method for treating Crohn's disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.

146. (New) A method for treating ulcerative colitis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

147. (New) A method for treating ulcerative colitis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

148. (New) A method for treating ulcerative colitis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

149. (New) A method for treating ulcerative colitis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.

150. (New) A method for treating inflammatory bowel disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 87.

151. (New) A method for treating inflammatory bowel disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 88.

152. (New) A method for treating inflammatory bowel disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 90.

153. (New) A method for treating inflammatory bowel disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 91.